Over the three months to March, the medical supplies distributor earned 96 cents a share, excluding one-time charges, a penny higher than analysts surveyed by Thomson Reuters forecast.
Unadjusted net income of 97 cents a share was 5 cents higher than a year earlier and beat estimates by 2 cents.
Revenue climbed 2.4% year over year to $2.59 billion. Analysts had expected $2.61 billion.
Management reiterated full-year guidance of 2% to 5% revenue growth, assuming a range of $10.44 billion to $10.75 billion. Analysts expect 4.1% growth or total revenue of $10.65 billion.
By late afternoon, shares were down 2.6% to $69.10.
Must read: Warren Buffett's 10 Favorite Growth Stocks